Liso-cel

Phase 3Biologic

JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Liso-cel is one of 143 biologic programs targeting Central Nervous System Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Nervous System LymphomaActive, not recruiting

LymphomaRecruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Follicular LymphomaActive, not recruiting

Central Nervous System LymphomaPhase 2

Active, not recruiting

LymphomaPhase 2

Recruiting

Chronic Lymphocytic LeukemiaPhase 3

Active, not recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Liso-cel

JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Lymphoma

NCT05621096

Q4 2028

Phase 2Recruiting

Lymphoma

NCT07015242

Clinical

Trials by Indication[1]

Lymphoma2 trials

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·UUniversity of Nebraska·Phase 1·NCT05621096·33 enrolled

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·NCT07015242·65 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06205290

Follicular Lymphoma1 trial

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06313996

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Liso-cel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liso-cel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liso-cel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Liso-cel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Lymphoma2 trials

Chronic Lymphocytic Leukemia1 trial

Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News